development of innovative treatments for pancreatic cancer
We strive to develop novel therapies that can revolutionize cancer treatment, providing patients with new hope and improved outcomes
Silexion Company Profile
Silexion Therapeutics is a pioneering developmental stage company dedicated to the development of innovative treatments for pancreatic cancer.
The company conducted phase 2 clinical trial with its first generation product which has shown positive efficacy results vs the control of chemotherapy alone.
Silexion’s commitment to pushing the boundaries of therapeutic advancements in the field of oncology, is focused in enhancing its first-generation product (LODERTM) to develop a new formulated product which will improve the clinical efficacy that Silexion observed with its first-generation product against pancreatic cancer.
Core Technologies
RNA Interference (RNAi)
Targeted Drug Delivery
Our vision is to establish treatment dedicated to addressing the complex and devastating impact of cancer on individuals and communities worldwide.
SIL-204- Silexion Product
Silexion Technology is a platform technology consisting of siRNA and PLG microparticle product for the treatment of solid tumors.
Second generation, SIL-204 is designed to inhibit KRAS oncogenic process in Pancreatic Cancer by delivering siRNA to eliminate the messengers (mRNA) of the G12V and G12D, mutant KRAS oncogenes to the cellular machinery.
Small interfering RNA (siRNA) microparticles will be administered directly into Pancreatic Cancer tumors, by standard endoscopy, with the microparticles slowly and continuously releasing the siRNA over an extended period of 2-3 months.
As we are administering SIL-204 intratumorally, it is important to note that distant metastasis in pancreatic cancer appears to come from the primary tumor (Yachida, S. et al. 2010. Nature. 467:1114). Treating the primary tumor can therefore also reduce new metastases.
Why SIL 204?
- Improve siRNA delivery by formulating into bioabsorbable PLG microparticles of about 30-70 µm that will release siRNA for 2-3 months in the pancreatic tumor.
- Add siRNA with a stronger inhibition profile towards G12V, and G12D, the most abundant mutants in Pancreatic Cancer.
- SIL 204 is delivered directly into the tumor and can be spread throughout the tumor surface area due to its liquid emulsion formulation.